Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Fulcrum Therapeutics (FULC) over the last 6 years, with Sep 2025 value amounting to $94,000.

  • Fulcrum Therapeutics' Capital Expenditures fell 38.16% to $94,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $409,000, marking a year-over-year increase of 27.02%. This contributed to the annual value of $278,000 for FY2024, which is 45.28% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Capital Expenditures of $94,000 as of Q3 2025, which was up 44.62% from $65,000 recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Capital Expenditures registered a high of $847,000 during Q1 2022, and its lowest value of $28,000 during Q1 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $94,000 (2025), whereas its average is $105,000.
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 294.62% in 2021, then plummeted by 83.63% in 2024.
  • Fulcrum Therapeutics' Capital Expenditures (Quarterly) stood at $519,000 in 2021, then slumped by 77.65% to $116,000 in 2022, then plummeted by 33.62% to $77,000 in 2023, then rose by 27.27% to $98,000 in 2024, then plummeted by 38.16% to $94,000 in 2025.
  • Its Capital Expenditures was $94,000 in Q3 2025, compared to $65,000 in Q2 2025 and $98,000 in Q4 2024.